Raw Ledipasvir Powder
Lokesh Adtecs Ltd.
Tamil Nadu, India


Raw Ledipasvir Powder

Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C.

The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

Synonyms: GS 5885;GS5885;GS-5885;Ledipasvir;GS-5885/Ledipasvir;gs-5885/gs5885;Ledipasvir / GS 5885;GS 588
CAS: 1256388-51-8
MF: C49H54F2N8O6
Molecular Weight: 889.0
Purity : 98%
Appearance : White powder